Mayne Pharma Group Limited announced it has launched an authorised generic (AG) of one of the larger dermatology products in the United States. Mayne Pharma entered into a license and supply agreement with one of the larger dermatology companies to distribute this product in non-retail channels.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.03 AUD | -1.13% | -1.12% | +14.47% |
02-26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
02-25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.47% | 367M | |
+20.79% | 43.34B | |
+20.80% | 21.96B | |
+13.30% | 14.09B | |
+13.29% | 13.64B | |
+39.44% | 11.43B | |
-9.70% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+9.64% | 5.22B |
- Stock Market
- Equities
- MYX Stock
- News Mayne Pharma Group Limited
- Mayne Pharma Expands U.S Dermatology Portfolio